Accessibility Menu
Neurotech International logo

Neurotech International(ASX) NTI

Market CapA$17.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-95%
5 Year-74%
1 Year-7%
1 Month-24%
A$0.01
+0.00%
+0.00Today
Neurotech International last closing stock price
MetricPriceDate
Last closeAUD 0.012026-08-13
Neurotech International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-18.75%AUD 0.022026-08-06
1 month-23.53%AUD 0.022026-07-14
3 month+8.33%AUD 0.012026-05-15
Year to date-7.14%AUD 0.012025-12-31
1 year-7.14%AUD 0.012025-08-13
3 year-70.45%AUD 0.042023-08-11
5 year-74%AUD 0.052021-08-13
Since inception-94.71%AUD 0.262016-11-04

Neurotech International Financials at a Glance

Market Cap

A$17.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.41M

Net Income (TTM)

-A$15.64M

EPS (TTM)

-A$0.00

P/E Ratio

-3.51

Dividend

A$0.00

Beta (Volatility)

-0.05 (Low)

Price

A$0.01

Volume

2,067,838

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.03

Estimated Earnings Date

Sep 2, 2026

NTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Neurotech International

Neurotech International Limited is an Australian company focused on the research, development, and manufacturing of innovative medical devices. The company specializes in advancing its Mente platform, which is designed to support home-based therapies, particularly for autism spectrum disorder.

Products and Services
  • Mente platform for home-based therapy monitoring
  • Mente Autism product for autism diagnosis and treatment
  • Various medical research projects and technological innovations
Growth Outlook
  • Significant focus on expanding the Mente platform's capabilities
  • Increased investment in research and development to drive innovation
  • Potential for partnerships in the healthcare sector to enhance market reach
Financial Highlights
  • Recent quarterly revenue of AUD 2,330,660, indicating market interest
  • Cash and cash equivalents increased to AUD 6,326,734, providing operational stability
  • Current ratio of 7.30 suggests strong liquidity position
Neurotech International Limited operates in the medical devices sector, with a strong emphasis on developing solutions for autism. The Mente platform represents a significant innovation in home-based therapy, which is increasingly relevant in today's healthcare landscape. The company's commitment to research and development is evident in its substantial investments, which are aimed at enhancing product offerings and expanding market presence. The financial position of Neurotech is characterized by a healthy cash balance, which supports ongoing operations and development initiatives. The current ratio indicates that the company is well-positioned to meet its short-term obligations, reflecting a solid liquidity position. Recent revenue figures demonstrate a growing interest in the company's products, suggesting potential for future growth. Overall, Neurotech International Limited presents an intriguing opportunity for investors interested in the healthcare and medical device sectors, particularly in innovative solutions for autism treatment.
AI Generated • Jul 22, 2026

Industry

Healthcare Equipment and Supplies

CEO

Anthony Filippis, PhD, MBA

Headquarters

Melbourne, VI 3000, AU

NTI Financials

Key Financial Metrics (TTM)

Gross Margin

344.17%

Operating Margin

-145.02%

Net Income Margin

-165.21%

Return on Equity

-87.19%

Return on Capital

-375.29%

Return on Assets

-56.54%

Earnings Yield

-28.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$17.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.32B

Volume

2.07M

Avg. Volume

1.79M

Financials (TTM)

Gross Profit

A$179.33K

Operating Income

-A$23.60M

EBITDA

-A$20.66M

Operating Cash Flow

-A$12.79M

Capital Expenditure

-A$8.00

Free Cash Flow

-A$12.79M

Cash & ST Invst.

A$6.34M

Total Debt

A$0.00

Neurotech International Performance Analysis

Neurotech International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 38,262N/A
20232023-06-30AUD 5,959-84.4%
20242024-06-30AUD 1,963-67.1%
20252025-06-30AUD 238-87.9%
Neurotech International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-2306.0%
Q22024-12-31442.1%
Q42025-06-301949.5%
Q22025-12-31-100.0%
Neurotech International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.01104.2%
20242024-06-30AUD -0.01-42.9%
20252025-06-30AUD -0.0182.1%
Neurotech International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-475.0%
Q22024-12-31-58.7%
Q42025-06-3058.9%
Q22025-12-31123.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

A$17.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$955.31K

N/A

Employees

18

N/A

Net Income

-A$696.50K

+4.4%

EBITDA

-A$5.43M

-39.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$6.34M

+41.6%

Total Debt

A$0.00

N/A

Accounts Receivable

A$375.08K

+99.6%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-56.54%

N/A

Return on Invested Capital

-57.51%

N/A

Free Cash Flow

-A$38.33K

+95.6%

Operating Cash Flow

-A$38.33K

+95.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGH.AXAlthea Group Holdings Limited
A$0.02-4.76%
AT1.AXAtomo Diagnostics Limited
A$0.02-5.56%
MDR.AXMedAdvisor Limited
A$0.02+0.00%
BTC.AXBTC Health Limited
A$0.06+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About NTI

What is the current price of Neurotech International?

Neurotech International is trading at A$0.01 per share.

What is the 52-week range for Neurotech International?

Over the past 52 weeks, Neurotech International has traded between A$0.01 and A$0.03.

How much debt does Neurotech International have?

As of the most recent reporting period, Neurotech International reported total debt of A$0.00.

How much cash does Neurotech International have on hand?

Neurotech International reported A$3.03M in cash and cash equivalents in its most recent financial results.

What is Neurotech International’s dividend yield?

Neurotech International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.